Literature DB >> 33714986

Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer.

Qun Chen1,2, Peng Shen1,2, Wan-Li Ge1,2, Tao-Yue Yang1,2, Wu-Jun Wang3, Ling-Dong Meng1,2, Xu-Min Huang1,2, Yi-Han Zhang1,2, Shou-Ji Cao1,2, Yi Miao1,2, Kui-Rong Jiang4,5, Jing-Jing Zhang6,7.   

Abstract

Pancreatic cancer (PC) is highly malignant and has a high mortality with a 5-year survival rate of less than 8%. As a member of the roundabout immunoglobulin superfamily of proteins, ROBO1 plays an important role in embryogenesis and organogenesis and also inhibits metastasis in PC. Our study was designed to explore whether ROBO1 has effects on the proliferation of PC and its specific mechanism. The expression of ROBO1 was higher in cancer tissues than in matched adjacent tissues by immunohistochemistry (IHC) and qRT-PCR. Low ROBO1 expression is associated with PC progression and poor prognosis. Overexpression of ROBO1 can inhibit the proliferation of PC cells in vitro, and the S phase fraction can also be induced. Further subcutaneous tumor formation in nude mice showed that ROBO1 overexpression can significantly inhibit tumor growth. YY1 was found to directly bind to the promoter region of ROBO1 to promote transcription by a luciferase reporter gene assay, a chromatin immunoprecipitation (ChIP) and an electrophoretic mobility shift assay (EMSA). Mechanistic studies showed that YY1 can inhibit the development of PC by directly regulating ROBO1 via the CCNA2/CDK2 axis. Taken together, our results suggest that ROBO1 may be involved in the development and progression of PC by regulating cell proliferation and shows that ROBO1 may be a novel and promising therapeutic target for PC.

Entities:  

Year:  2021        PMID: 33714986     DOI: 10.1038/s41388-021-01741-5

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  ROBO1 p.E280* Loses the Inhibitory Effects on the Proliferation and Angiogenesis of Wild-Type ROBO1 in Cholangiocarcinoma by Interrupting SLIT2 Signal.

Authors:  Tao Zhou; Yaodong Zhang; Yananlan Chen; Jijun Shan; Jifei Wang; Yirui Wang; Jiang Chang; Wangjie Jiang; Ruixiang Chen; Ziyi Wang; Xiaoli Shi; Yue Yu; Changxian Li; Xiangcheng Li
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

2.  Systematic Review With Meta-Analysis: Diagnostic, Prognostic and Clinicopathological Significance of CircRNA Expression in Renal Cancer.

Authors:  Wujun Wang; Shengfang Xie; Dongping Yuan; Dandan He; Liming Fang; Fengfeng Ge
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

3.  CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types.

Authors:  Aimin Jiang; Ye Zhou; Wenliang Gong; Xin Pan; Xinxin Gan; Zhenjie Wu; Bing Liu; Le Qu; Linhui Wang
Journal:  Oxid Med Cell Longev       Date:  2022-03-31       Impact factor: 6.543

4.  6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway in HeLa cells.

Authors:  Chaihong Zhang; Yuchong Quan; Lijuan Yang; Yingying Bai; Yongxiu Yang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

5.  Characterization of Cell Cycle-Related Competing Endogenous RNAs Using Robust Rank Aggregation as Prognostic Biomarker in Lung Adenocarcinoma.

Authors:  Yifei Yang; Shiqi Zhang; Li Guo
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

6.  The Predictive Competing Endogenous RNA Regulatory Networks and Potential Prognostic and Immunological Roles of Cyclin A2 in Pan-Cancer Analysis.

Authors:  Shenyong Chen; Zhijia Zhao; Xiaobo Wang; Qi Zhang; Li Lyu; Bo Tang
Journal:  Front Mol Biosci       Date:  2022-04-11

7.  Roundabout Guidance Receptor 1 Is an Emerging Prognostic Biomarker for Nasopharyngeal Carcinoma.

Authors:  Sung-Wei Lee; Ching-Chieh Yang; Hong-Yue Lai; Hsin-Hwa Tsai; Cheng-Fa Yeh; Yu-Hsuan Kuo; Nai-Wen Kang; Tzu-Ju Chen; Shih-Lun Chang
Journal:  Clin Med Insights Oncol       Date:  2022-07-22

8.  ROBO3s: a novel ROBO3 short isoform promoting breast cancer aggressiveness.

Authors:  Marcel Werner; Anna Dyas; Iwan Parfentev; Geske E Schmidt; Iga K Mieczkowska; Lukas C Müller-Kirschbaum; Claudia Müller; Stefan Kalkhof; Oliver Reinhardt; Henning Urlaub; Frauke Alves; Julia Gallwas; Evangelos Prokakis; Florian Wegwitz
Journal:  Cell Death Dis       Date:  2022-09-03       Impact factor: 9.685

9.  Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer.

Authors:  Niklas Krebs; Lukas Klein; Florian Wegwitz; Elisa Espinet; Hans Carlo Maurer; Mengyu Tu; Frederike Penz; Stefan Küffer; Xingbo Xu; Hanibal Bohnenberger; Silke Cameron; Marius Brunner; Albrecht Neesse; Uday Kishore; Elisabeth Hessmann; Andreas Trumpp; Philipp Ströbel; Rolf A Brekken; Volker Ellenrieder; Shiv K Singh
Journal:  JCI Insight       Date:  2022-08-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.